Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2022-11, Vol.140 (Supplement 1), p.9331-9332
Hauptverfasser: Ailawadhi, Sikander, Parrondo, Ricardo D, Laplant, Betsy, Alegria, Victoria R., Elliott, Jamie B, Zimmerman, Ashley, Heslop, Keisha, Chapin, Dustin, Sher, Taimur, Roy, Vivek, Rasheed, Ahsan, Paulus, Aneel, Chanan-Khan, Asher
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 9332
container_issue Supplement 1
container_start_page 9331
container_title Blood
container_volume 140
creator Ailawadhi, Sikander
Parrondo, Ricardo D
Laplant, Betsy
Alegria, Victoria R.
Elliott, Jamie B
Zimmerman, Ashley
Heslop, Keisha
Chapin, Dustin
Sher, Taimur
Roy, Vivek
Rasheed, Ahsan
Paulus, Aneel
Chanan-Khan, Asher
description
doi_str_mv 10.1182/blood-2022-165377
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_165377</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122057627</els_id><sourcerecordid>S0006497122057627</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1857-e81ad51b5ae0ea75307870fc410a161a9e8622d495b83a4722f76a5a548392403</originalsourceid><addsrcrecordid>eNp9kM9KxDAQh4MouK4-gLcc9VCdpE2T4kkW_xR2cUFlj2Hapm6kbSTpquuD-QK-mNV69jQwP77hNx8hxwzOGFP8vGicqyIOnEcsFbGUO2TCBFcRAIddMgGANEoyyfbJQQjPACyJuZiQdrnGYGie0_t-U22pq2le-E1vO1tQ29GZawvbYW9dR99sv6b5O364dgyXw950fRiTFTaV6ULvvz5busDSu6fGFZvGdqa1SE9Wi9NDsldjE8zR35ySx-urh9ltNL-7yWeX86hkSsjIKIaVYIVAAwaliEEqCXWZMECWMsyMSjmvkkwUKsZEcl7LFAWKRMUZTyCeEjbeHUqE4E2tX7xt0W81A_3jS__60j--9OhrYC5GxgzFXq3xOpTDd6WprDdlrytn_6G_AZf4c5o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Ailawadhi, Sikander ; Parrondo, Ricardo D ; Laplant, Betsy ; Alegria, Victoria R. ; Elliott, Jamie B ; Zimmerman, Ashley ; Heslop, Keisha ; Chapin, Dustin ; Sher, Taimur ; Roy, Vivek ; Rasheed, Ahsan ; Paulus, Aneel ; Chanan-Khan, Asher</creator><creatorcontrib>Ailawadhi, Sikander ; Parrondo, Ricardo D ; Laplant, Betsy ; Alegria, Victoria R. ; Elliott, Jamie B ; Zimmerman, Ashley ; Heslop, Keisha ; Chapin, Dustin ; Sher, Taimur ; Roy, Vivek ; Rasheed, Ahsan ; Paulus, Aneel ; Chanan-Khan, Asher</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-165377</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.9331-9332</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1857-e81ad51b5ae0ea75307870fc410a161a9e8622d495b83a4722f76a5a548392403</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Ailawadhi, Sikander</creatorcontrib><creatorcontrib>Parrondo, Ricardo D</creatorcontrib><creatorcontrib>Laplant, Betsy</creatorcontrib><creatorcontrib>Alegria, Victoria R.</creatorcontrib><creatorcontrib>Elliott, Jamie B</creatorcontrib><creatorcontrib>Zimmerman, Ashley</creatorcontrib><creatorcontrib>Heslop, Keisha</creatorcontrib><creatorcontrib>Chapin, Dustin</creatorcontrib><creatorcontrib>Sher, Taimur</creatorcontrib><creatorcontrib>Roy, Vivek</creatorcontrib><creatorcontrib>Rasheed, Ahsan</creatorcontrib><creatorcontrib>Paulus, Aneel</creatorcontrib><creatorcontrib>Chanan-Khan, Asher</creatorcontrib><title>Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kM9KxDAQh4MouK4-gLcc9VCdpE2T4kkW_xR2cUFlj2Hapm6kbSTpquuD-QK-mNV69jQwP77hNx8hxwzOGFP8vGicqyIOnEcsFbGUO2TCBFcRAIddMgGANEoyyfbJQQjPACyJuZiQdrnGYGie0_t-U22pq2le-E1vO1tQ29GZawvbYW9dR99sv6b5O364dgyXw950fRiTFTaV6ULvvz5busDSu6fGFZvGdqa1SE9Wi9NDsldjE8zR35ySx-urh9ltNL-7yWeX86hkSsjIKIaVYIVAAwaliEEqCXWZMECWMsyMSjmvkkwUKsZEcl7LFAWKRMUZTyCeEjbeHUqE4E2tX7xt0W81A_3jS__60j--9OhrYC5GxgzFXq3xOpTDd6WprDdlrytn_6G_AZf4c5o</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Ailawadhi, Sikander</creator><creator>Parrondo, Ricardo D</creator><creator>Laplant, Betsy</creator><creator>Alegria, Victoria R.</creator><creator>Elliott, Jamie B</creator><creator>Zimmerman, Ashley</creator><creator>Heslop, Keisha</creator><creator>Chapin, Dustin</creator><creator>Sher, Taimur</creator><creator>Roy, Vivek</creator><creator>Rasheed, Ahsan</creator><creator>Paulus, Aneel</creator><creator>Chanan-Khan, Asher</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)</title><author>Ailawadhi, Sikander ; Parrondo, Ricardo D ; Laplant, Betsy ; Alegria, Victoria R. ; Elliott, Jamie B ; Zimmerman, Ashley ; Heslop, Keisha ; Chapin, Dustin ; Sher, Taimur ; Roy, Vivek ; Rasheed, Ahsan ; Paulus, Aneel ; Chanan-Khan, Asher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1857-e81ad51b5ae0ea75307870fc410a161a9e8622d495b83a4722f76a5a548392403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ailawadhi, Sikander</creatorcontrib><creatorcontrib>Parrondo, Ricardo D</creatorcontrib><creatorcontrib>Laplant, Betsy</creatorcontrib><creatorcontrib>Alegria, Victoria R.</creatorcontrib><creatorcontrib>Elliott, Jamie B</creatorcontrib><creatorcontrib>Zimmerman, Ashley</creatorcontrib><creatorcontrib>Heslop, Keisha</creatorcontrib><creatorcontrib>Chapin, Dustin</creatorcontrib><creatorcontrib>Sher, Taimur</creatorcontrib><creatorcontrib>Roy, Vivek</creatorcontrib><creatorcontrib>Rasheed, Ahsan</creatorcontrib><creatorcontrib>Paulus, Aneel</creatorcontrib><creatorcontrib>Chanan-Khan, Asher</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ailawadhi, Sikander</au><au>Parrondo, Ricardo D</au><au>Laplant, Betsy</au><au>Alegria, Victoria R.</au><au>Elliott, Jamie B</au><au>Zimmerman, Ashley</au><au>Heslop, Keisha</au><au>Chapin, Dustin</au><au>Sher, Taimur</au><au>Roy, Vivek</au><au>Rasheed, Ahsan</au><au>Paulus, Aneel</au><au>Chanan-Khan, Asher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>9331</spage><epage>9332</epage><pages>9331-9332</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-165377</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-11, Vol.140 (Supplement 1), p.9331-9332
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2022_165377
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T15%3A21%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20Study%20of%20Ibrutinib%20in%20Combination%20with%20Ixazomib%20in%20Patients%20with%20Waldenstr%C3%B6m%20Macroglobulinemia%20(WM)&rft.jtitle=Blood&rft.au=Ailawadhi,%20Sikander&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=9331&rft.epage=9332&rft.pages=9331-9332&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-165377&rft_dat=%3Celsevier_cross%3ES0006497122057627%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122057627&rfr_iscdi=true